stockrow
Saturday 7 November 2026
Export HELP’s income statement to Excel — free account
Cybin Inc.
HELP Healthcare Biotechnology
- EPS
- +17.3%
- Free cash flow
- −25.6%
Quarter to June 2026, against a year earlier
8.96
0.57
+6.79%
Follow HELP
Alert me
Cybin Inc. (HELP) P/E ratio
Cybin Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| HELP Cybin Inc. | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| GERN Geron Corporation compare | n/m |
| CADL Candel Therapeutics, Inc. compare | n/m |
| ZVRA Zevra Therapeutics, Inc. compare | 9.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)